Abstract Macrophages are heterogeneous innate immune cells which are important in both the maintenance of tissue homeostasis and its disruption, by promoting tissue inflammation and fibrosis. The renin-angiotensin system is central to the pathophysiology of a large suite of diseases, which are driven in part by large amounts of tissue inflammation and fibrosis. Here, we review recent advances in understanding macrophage heterogeneity in origin and function, and how these may lead to new insights into the pathogenesis of these chronic diseases.
Introduction
Inflammation and wound healing are essential biological processes activated in response to alterations in tissue homeostasis [60] . Inflammation is necessary to eliminate infiltrated pathogens or damaged cells, recruit other immune cells to the site of damage and, if necessary, activate adaptive immunity. Conversely, wound healing involves the regeneration of cells and deposition of extracellular matrix proteins such as collagen, to enhance barrier reformation and organ repair.
Under homeostatic conditions, inflammation and wound healing are balanced, resulting in, for example, the efficient removal of the pathogen without excessive destruction to the surrounding tissue, restoration of the barrier and repair of organ function. However, when inflammation and/or wound healing are not appropriate, this can quickly manifest into loss of organ function and disease [9] . In situations of excessive or unresolved chronic inflammation, large numbers of leucocytes are recruited to the tissue, releasing cytokines and reactive oxygen species that cause non-specific damage to the tissue. By contrast, when repair processes are abnormal, excessive deposition of collagen can result in remodelling of the extracellular matrix, formation of scar tissue and organ failure [59] .
Key elements of both inflammation and wound healing are mediated by a type of innate immune cells known as macrophages [60] . Macrophages are a phagocytic, mononuclear cell type with important and extremely diverse roles in responding to infection, promoting inflammation, wound repair and maintaining tissue homeostasis. Understanding the drivers and regulators of macrophage function, and more importantly, how this can go awry and lead to aberrant inflammation and fibrosis, is of key interest to researchers of many disciplines. Here, we review recent studies which have increased knowledge of the complexity and heterogeneity of macrophage cellular biology. We then address the role of macrophages in the development of chronic diseases related to the renin-angiotensin system, and how these new insights into macrophage cellular biology may shed light on these disorders.
Macrophage function(s)
Macrophages are perhaps best characterised by their proinflammatory role in anti-pathogen immunity [39] . Located in every tissue in the body, together with their cousins, the dendritic cells, they are often referred to as the 'sentinels of the immune system', due to their ability to distinguish self from non-self and clear foreign microorganisms by phagocytosis. Macrophages are usually the first immune cells to respond to infection, and they express a diversity of pattern recognition receptors that recognise both conserved structures common to many pathogens (pathogen-associated molecular patterns-PAMPs) and also endogenous biomolecules released only by damaged, stressed and dying cells (damage-associated molecular patterns-DAMPs). Macrophages respond to these stimuli by secreting chemokines and pro-inflammatory cytokines such as interleukin (IL)-1β, tumour necrosis factor (TNF)-α and IL-6, which collectively activate and recruit other leucocytes to the site of infection/ inflammation in order to combat infection [39] . Moreover, macrophages are professional antigen-presenting cells and engage in a bi-directional dialogue with T lymphocytes of the adaptive immune system. Whilst generally considered to lack the ability to initiate naïve T lymphocyte responses [54] , they can amplify existing T cell responses and steer the differentiation of T cells into pro-inflammatory effector cells such as T helper 1 (Th1) and T helper 17 (Th17) [2, 31] . In return, macrophages can receive activation signals from effector T cells to express high levels of reactive oxygen species and so become superb killers of ingested microorganisms [39] . By contrast, macrophages can also have anti-inflammatory roles and are involved in the resolution of inflammation, the phagocytosis of cellular debris, in wound healing (as described above) and the suppression of T cell proliferation [22] . Moreover, macrophages have many important non-immune roles in tissue development and homeostasis [61] . The phagocytic ability of macrophages is used to remove aged and apoptotic cells from the body [13] , with the classical example being splenic macrophages that remove and phagocytose aged erythrocytes and neutrophils from the circulation [23] . Similarly, the phagocytic activity of osteoclasts, a specialised macrophage found in the bone, has an important role in bone resorption, and an impairment in osteoclast function leads to osteopetrosis, a disease which results in skeletal fragility, despite increased bone mass [45] . Finally, microglia, the specialised macrophages of the central nervous system, have essential roles in the formation and maintenance of neural circuitry and brain structure [19] . How then can we explain this incredible heterogeneity in macrophage function? Recent advances reveal two sources of macrophage heterogeneity: diversity in ontogeny and activation.
Macrophage heterogeneity: ontogeny
Macrophages are unique in that they are the only immune cells derived from two developmental origins: progenitors that arise in the yolk sac and/or foetal liver during embryogenesis, and also from haematopoietic stem cells, which give rise to macrophage and dendritic cell precursors (MDPs), and finally monocytes, throughout adulthood ( Fig. 1) [42] . Macrophages derived from embryonic precursors are known as tissue-resident macrophages (TRMs), as they are effectively seeded during the development of their respective tissues and permanently reside throughout adulthood with limited renewal from haematopoietic precursors. Many different TRMs have now been identified and characterised, each with a specialised homeostatic function distinct to the tissue in which they reside. As mentioned above, brain-resident macrophages, known as microglia, are important in maintaining axonal excitability; lung-resident alveolar macrophages preserve surfactant homeostasis; liver-resident macrophages are Kupffer cells; Langerhans cells are macrophages resident in the skin and may have a key role in promoting immune tolerance [18, 42, 44, 52] . TRMs have also been identified and characterised in the peritoneal cavity [29] , gut [4] , kidney [53] , arterial wall [16] and heart [17] . Recently, the transcriptional and regulatory network of a number of different TRMs has been extensively characterised [24, 32] . This significant body of work demonstrated TRMs from different tissues have distinct transcriptional, enhancer and regulatory profiles. Strikingly, these profiles appear to be plastic and highly reliant on the microenvironment in which each TRM is located: when monocyte-derived macrophages were transplanted to fill an empty TRM niche, their transcriptional profile was found to be highly similar to those of embryonic TRMs, indicating an acquisition of TRM phenotype [32, 50] .
By contrast, primarily during inflammatory responses, tissues are invaded by monocyte-derived macrophages in response to specialised cues. In homeostatic conditions, the principal driver of monocyte/macrophage differentiation is the cytokine, colony stimulating factor 1 (CSF-1, M-CSF) (Fig. 1) [25] . CSF-1 has pleotropic effects: it regulates the mobilisation of monocytes and is a critical regulator of the differentiation, proliferation and survival of monocyte-derived tissue macrophages [25] . CSF-1 is not the only cytokine that can stimulate macrophage differentiation, for example under inflammatory conditions (like in the presence of inteferon-gamma (IFN-γ)); granulocyte macrophage colony stimulating factor (GM-CSF) plays a critical role [26] . There are a number of different chemoattractants and adhesion molecules that drive the transmigration of monocytes into tissues from the vasculature. Here, TRMs play a key role as the initial immune cells to detect Bdanger^through their pattern recognition receptors, and their subsequent secretion of chemokines, such as chemokine (C-X-C motif) ligand 2 (CXCL2) and macrophage migration inhibitory factor (MIF) [48] . Thus, to arrive in the tissues, blood-born monocytes must communicate with endothelium that has been activated by the release of chemoattractants (either from TRM or other cells within the tissue). Here, like other leucocytes, monocytes follow the general paradigm of the leucocyte adhesion cascade [33, 51] . Monocytes use all three members of the selectin family, as well as the integrin α4β1 to initiate rolling on the inflamed vasculature. Inflammatory monocytes express the chemokine receptor CCR2 which recognises its ligands CXCL2 and MIF, and the subsequent activation of both α4β1 and β2 integrins contributes to monocyte tight adhesion to the endothelium.
Macrophage heterogeneity: activation
Within the tissue, the presence of molecules including other cytokines, small metabolites, and foreign pathogens, can induce the further activation of monocyte-derived macrophages into functionally distinct subpopulations ( Fig. 1 ) [38] . Depending on the concentration and combination of stimuli, macrophages can be activated into a large spectrum of phenotypes; ranging from pro-inflammatory to anti-inflammatory effector functions. Macrophage function is therefore finely tuned to minute alterations in their local tissue microenvironment or milieu.
This heterogeneous spectrum of macrophage activation phenotypes was previously simplified into two discrete states: pro-inflammatory macrophages were referred to as Bclassically activated^or BM1^, while anti-inflammatory were named Balternatively activated^or BM2^. However, there is now consensus that this terminology of M1 and M2 is an oversimplification that does not reflect the complete heterogeneity of macrophage activation, particularly in vivo [38] . Hence, for in vitro studies, a new nomenclature system has been recently proposed whereby the stimuli used to activate is indicated in parentheses; for example, LPS-stimulated macrophages are described as BM(LPS)^, IL-4-stimulated as BM(IL-4)^and so on [38] . No matter what macrophages are called, there is appreciation that it is not only the presence but the phenotypic balance of pro-and anti-inflammatory macrophages within the tissue that is crucial to establishing an adequate amount of inflammation and wound healing in response to alterations in homeostasis [9, 34, 47, 60] . Generally, proinflammatory-activated macrophages, for example those which encounter gram-negative bacterium or IFN-γ, can be generally characterised as cells which secrete pro-inflammatory molecules leading to enhanced tissue inflammation and the activation of adaptive immunity (Fig. 1) . Conversely, anti- are derived from embryonic precursors at the yolk sac or foetal liver stages and thereafter populate their respective tissue throughout adulthood. Conversely, monocyte-derived macrophages are generated from circulating haematopoietic stem cells, which differentiate in to MDPs, which then derive circulating monocytes. CSF-1 regulates the mobilisation of monocytes and their differentiation, proliferation and survival as tissue monocyte-derived macrophages. As sentinels of tissue homeostasis, when alterations are detected, TRMs can secrete the chemoattractants CXCL2 and MIF that drive the invasion of monocytederived macrophages. Within the tissue, monocyte-derived macrophages can then further acquire a spectrum of phenotypes, depending on the combination and concentration of stimulatory cues such as pathogens and cytokines. Macrophages with a pro-inflammatory phenotype can have multiple functions, including the elimination of pathogens and processing and presentation of antigen. Under disease settings (red font), such as the over-activation of the renin-angiotensin system, excessive numbers and activation of pro-inflammatory macrophages can lead to chronic inflammation and non-specific damage to organs. At the other end of the activation spectrum, macrophages with an anti-inflammatory phenotype instead have functions including the repair and remodelling of tissue and suppression of pro-inflammatory immune cells. In disease settings, excessive anti-inflammatory macrophage activation can cause aberrant tissue repair, eventually resulting in fibrosis and loss of organ function. Abbreviations: MDP monocyte and dendritic cell precursor, CSF-1 colony-stimulating factor 1, LPS lipopolysaccharide, IFN-γ interferon gamma, CXCL2 chemokine (C-X-C motif) ligand 2, MIF macrophage migration inhibitory factor, MHC II major histocompatibility complex class II, PD-L1 programmed death-ligand 1 or CD274, CD38 cyclic ADP ribose hydrolase, NO nitric oxide, TNF-α tumour necrosis factor alpha, IL-1β interleukin 1-beta, IL-6 interleukin 6, PD-L2 programmed death-ligand 2 or CD273, Mrc1 mannose receptor, Arg1 arginase 1, Fizz1 resistin-like molecule alpha, Ym1 chitinase-like protein 3, Mgl2 macrophage galactose N-acetyl-galatosamine specific lectin 2 inflammatory macrophages, for example those which are stimulated with the cytokines IL-4 and IL-13, are generally considered to promote tissue homeostasis by suppressing inflammatory responses and enhancing tissue repair (Fig. 1) . Thus, understanding molecular mechanisms key for generating and maintaining the phenotype of pro-and anti-inflammatoryactivated macrophages may be potential therapeutic targets for diseases characterised by excessive inflammation or fibrosis.
The renin-angiotensin system: beyond blood pressure regulation
Well-recognised roles of the renin-angiotensin system (RAS) are the regulation of blood pressure, sodium retention and vasoconstriction. This is a highly regulated system, involving the concerted action of multiple organs, peptides and enzymes; others have reviewed this cascade in greater detail [3] . The end-product of the RAS is an eight-residue peptide, angiotensin II (Ang II). Ang II is the major active effector in the cascade, via its actions on the type 1 angiotensin receptor (AT1R).
Abnormal activation of the RAS, resulting in elevated and sustained levels of Ang II, is a recognised driver of hypertension and, subsequently, end-organ damage, and is a feature of diabetes-related complications such as retinopathy, nephropathy and neuropathy (hereafter collectively referred to as BRAS disorders^). While hypertension can drive these diseases and complications, therapeutic reduction of blood pressure does not completely prevent or cure patients of these downstream disorders. Together, this has led to the idea that the RAS, and Ang II, has roles beyond those of blood pressure and water regulation, including both inflammation and fibrosis [5] . Increases in systemic levels of Ang II and/or activation of tissue-localised RAS results in the expression of endothelial adhesive molecules such as integrins, selectins and vascular cell adhesion molecule 1 (VCAM1) and chemoattractants such as CXCL2, ultimately resulting in an infiltration of leucocytes, including monocytes, into the tissue [15, 35, 36, 57, 58] . Infiltrated leucocytes, including macrophages, are thought to then initiate the inflammatory, remodelling and fibrotic processes that lead to organ failure in these diseases. In light of recent insights into macrophage biology (as discussed above), it is important to re-examine how RAS and Ang II may affect macrophage homeostasis and lead to disease.
Macrophages in RAS disorders
The infusion of Ang II into laboratory mice (usually C57Bl/6 or Sv129 background) is a common experimental model which induces a robust and sustained increase in blood pressure, ultimately leading to downstream organ dysfunction including kidney injury and cardiac hypertrophy (target organ damage). In this model, a massive increase in macrophages is evident in the kidney, heart and vasculature [14, 40, 43, 56] ; generally, this is determined by immunohistochemistry for F4/ 80 (also known as EMR1) or CD68 (also known as ED1); the so-called pan markers of macrophages which are expressed at varying levels on all TRMs and monocyte-infiltrating macrophages but also monocytes (Table 1) .
Vascular damage and dysfunction, such as arterial remodelling and stiffening, are considered to be both a hallmark of, and, causative in the pathogenesis of hypertension [37] . As mentioned above, in murine models of hypertension such as Ang II infusion, a dramatic increase in the number of macrophages/monocytes into the vascular wall has been observed [14, 56] . This is true also when hypertension is induced by high dietary salt in combination with deoxycorticosterone acetate (DOCA) [10] . The accumulation of macrophages/monocytes into vascular walls is subsequently associated with an elevation of inflammatory molecules and reactive oxygen species, eventually resulting in elevated vascular relaxation responses and the onset of hypertension [14, 56] . A causative role for macrophages/monocytes has been demonstrated by their depletion and subsequent attenuation of vascular inflammation, dysfunction and overall hypertension: mice were generated to be devoid of macrophages due to CSF-1 deficiency [14] , by inducible diphtheria toxin macrophage-specific depletion [56] , or by treatment with a chemical agonist of the macrophage-specific chemokine receptor, CCR2 [10] . Collectively, these studies indicate that targeting the infiltration and function of macrophages/ monocytes in the vascular wall may be effective therapeutics against RAS-induced hypertension.
Downstream of elevated blood pressure, the RAS additionally plays a role in the onset of the so-called end-organ damage to tissues such as the kidney and heart. Here, as a result of Ang II infusion, an elevation in the number of macrophages is observed in both the kidney [43] and heart [40] , resulting in inflammation and fibrosis and eventual loss of organ function. The same is true for diabetes complications associated with aberrant RAS activation. For example, in our own work, we have shown a causative pathological role for elevations in retinal macrophage/microglia and the onset of diabetic retinopathy, which can be prevented by RAS inhibition [15, 57, 58] . CCR2 knockout mice, which are deficient in monocytes, have a drastically reduced number of aortic-infiltrated macrophages in response to Ang II, resulting in attenuated fibrosis [8] . This finding indicated that Ang II may directly influence macrophage activation and function. To dissect this mechanism further in vivo, several groups have performed transplantation experiments with bone marrow from various knockout mice. For example, Crowley et al. investigated whether Ang II itself has a direct effect on immune cells and performed transplantation studies with AT1R (the major Ang II receptor)-deficient bone marrow (Agtr1
−/−
). This resulted in an augmented hypertensive response in mice transplanted with AT1R-deficient bone marrow and subjected to Ang II infusion, mediated by an increased number of F4/80 + myeloid cells in the kidney, suggesting that Ang II engagement with AT1R on macrophages restrains pro-inflammatory mechanisms [12] . Contrastingly, in a study of fibrosis-only kidney damage, unilateral ureteral obstruction (UUO), a divergence was observed in the number of F4/80 + myeloid cells and extent of kidney fibrosis. In this setting, AT1R deficiency restrained macrophage infiltration, but fibrosis was more pronounced [41] . Marko et al. investigated a downstream signalling effect of Ang II-ATIR ligation by transplanting Bcl10 −/− bone marrow, which do not have an active CBM signalosome, thus inhibiting the activation of NF-κB pro-inflammatory pathways by Ang II [35] . Upon transfer of Bcl10 −/− bone marrow and Ang II infusion, no difference in hypertension was observed, despite a reduction in monocyte/macrophage infiltration and attenuation of cardiac fibrosis [35] . Taken together, the precise and direct role of Ang II and other RAS components (not discussed here) on macrophage function and pathology remain unclear. We propose that recent advances in the surface phenotyping of macrophages, and thus, the degree of macrophage heterogeneity, may shed new light on the cellular mechanisms behind these abovementioned studies.
Tissue resident versus monocyte derived: which ones should we target?
What has not yet been fully considered in the context of Ang II and target-organ damage is the respective contribution of TRMs versus monocyte-derived macrophages in mediating these diseases. This has been limited by the overuse of pan macrophage markers like F4/80, which are expressed on both TRMs and monocyte-derived infiltrating macrophages, and to some extent, on monocytes (Table 1) . Advancements in the isolation of immune cells from tissues for analysis of flow cytometry has led to an increased understanding of the origin, identity and function of macrophages in tissues relevant to RAS disorders, including the kidney, heart and retina [24, 32] . Recently, Epelman et al. identified four macrophage subsets within steady-state adult cardiac tissue that share the common surface expression of F4/80 and CD11b but vary in the expression of the molecules MHC-II, Ly6c, CD64, MerTK, CD206 and CD11c (Table 1 ) [17] . While this may seem merely like immunological semantics, the authors further identified that these macrophage subsets have different origins (resident versus infiltrating) and subsequently altered mechanisms of turnover and function. Furthermore, Ang II infusion augmented proliferation of resident cardiac macrophage subsets (distinguished as CCR2 − ) and infiltrated monocyte-derived macrophages (distinguished as CCR2 + ); however, the amount of expansion varied between subsets; notably, infiltrating macrophage numbers (CCR2 + ) increased at the expense of CCR2 − -resident macrophages. This observation that tissue insult increases monocyte-infiltrating macrophages at the expense of TRMs has also been recently observed in studies of lung infection (Table 1) [7] . Epelman et al. also identified that functionally, resident cardiac macrophages were efficient immunosurveyors; phagocytosing dying cardiomyocytes and processing and presenting antigen via MHC-II. By contrast, CCR2
+ monocyte-infiltrated macrophages expressed high levels of pro-inflammatory molecules, particularly those involved with the NLRP3 inflammasome [17] . Taken together, this significant work provides an explanation for why broad depletion of macrophages (which target both monocyte and resident macrophages) are not protective. Instead, strategies should be developed to prevent monocyte influx, which in this setting appear to be the mediators of inflammation, while maintaining homeostatic tissue-resident macrophage function.
Other tissues susceptible to Ang II-mediated inflammation and fibrosis include the kidney and retina; both of which have resident macrophages. Recently, in a model of type III hypersensitivity, kidney-resident macrophages were shown to directly mediate a kidney inflammatory response upon detection of immune complexes (Table 1 ) [53] . Whether kidney-resident macrophages mediate an inflammatory response upon RAS activation, or rather, the relative role of TRM versus monocyte-infiltrating macrophages upon RAS activation has not yet been directly assessed. However, in the UUO study by Nishida et al. (described above, [41] ), Agtr1 −/− macrophages were shown to have a reduced phagocytic ability, but a preserved oxidative capacity, indicating Ang II may play an important role in homeostatic kidney-resident macrophage function. In the retina (and brain), microglia are the resident macrophage of interest. Microglia have been shown to seed the tissue extremely early in development [21] , with strikingly no replenishment from monocyte-derived macrophages in adulthood [17] and instead, their numbers are maintained and expanded locally through proliferation [1, 49] . In the context of retinopathy, we [15, 57, 58] and others have observed an increased number of Bmicroglia^upon RAS activation. However, commonly used markers such as Iba1, CD68 and F4/80 are expressed in both microglia and monocyte-derived macrophages. Furthermore, it is not clear whether microglia have the capacity to initiate inflammation and fibrosis like their monocyte-derived counterparts; in fact, there is mounting evidence that microglia do not share this capacity to become Bactivated^into specific phenotypes [46] . In light of recent advances in the demarcation of microglia from monocyteinfiltrating macrophages by flow cytometry (Table 1 ) [32] , these models could be re-addressed and, like the strategy of Epelman et al., the relative contribution of microglia and monocyte-derived macrophages in mediating retinal inflammation and damage can be distinguished.
Macrophage activation in the context of RAS diseases
As described above, the appearance of a Bmacrophage^within a tissue can functionally mean a multitude of things; for example, this could be a resident macrophage maintaining tissue homeostasis by phagocytosing dying cells, or perhaps a monocyte-infiltrating macrophage clearing an intracellular pathogen. Thus, in order to understand the relative role of this macrophage in mediating RAS diseases, identifying its phenotype is crucial. There has been a large reliance in the field on the M1 and M2 nomenclature, and the use of markers Bspecific^to these activation states. For example, CD206 (mannose receptor, MRC1), a C-type lectin important in phagocytosis and the scavenging of mannoglycoproteins, is a commonly used marker for anti-inflammatory M2 macrophages. In vitro stimulation of bone marrow-derived macrophages with IL-4 and IL-13 does drive the increased surface expression of this protein. However, in vivo, it is also expressed on cardiac-resident macrophages [17] and used as a general marker of human adipose tissue macrophages [62] . One would also expect pathogens which utilise the mannose metabolic pathway to alter macrophage surface expression of CD206. Conversely, nitric oxide synthase (iNOS) is used as a specific marker for pro-inflammatory M1 macrophages, as it is significantly upregulated in macrophages stimulated with Th1 mediators such as lipopolysaccharides (LPS) and other endotoxins and the pro-inflammatory cytokine IFN-γ. However, it is not known if Ang II infusion induces high tissue levels of endotoxins or M1-or M2-specific cytokines like IFN-γ and IL-4, respectively. Thus, we suggest that M1 and M2 Bspecific^markers like CD206 and iNOS, which are induced in vitro under specific stimulatory co nditions with pro-and anti-inflammatory molecules and cytokines, may not similarly be induced in vivo in response to systemic Ang II infusion, which is likely to result in the altered expression of a complex milieu of many cytokines in varying concentrations. In other words, the specific surface markers expressed by proand anti-inflammatory macrophages in response to Ang II is not known. This same question was asked by Kratz et al., who undertook a proteomics approach to identify surface markers of macrophages isolated from the adipose tissue of obese humans and mice [30] . Strikingly, M1 markers which were induced upon stimulation in vitro with LPS and IFN-γ (e.g. PD-L1, CD38) were absent from macrophages directly isolated from adipose tissue. Nonetheless, these adipose macrophages displayed a pro-inflammatory BM1^phenotype, as they demonstrated elevated expression of pro-inflammatory cytokines TNF-α, IL1β and IL-6 [30] . In light of the numerous recent studies showing how distinct the transcriptional profiles of tissue-resident macrophages are, largely because of the sensitivity of macrophages to their local tissue environment, it seems plausible that there would be changes in the panel of surface molecules expressed on pro-and antiinflammatory macrophages within different tissues. Furthermore, in the setting of disease, the tissue milieu of cytokines, small metabolites [11, 55] and even electrolytes [6, 27, 28] is highly likely to vary and thereby further modulate the response of the TRM or infiltrated macrophage; thus again, alter the surface expression of proteins. In summary, there are multiple activation pathways which lead to the acquisition of a pro-inflammatory or pro-fibrotic macrophage phenotype, and which pathway is activated may differ substantially between tissues and more so when further tissue insult, such as increased levels of Ang II, is present. We hope that a similar approach to those recent studies we have highlighted here in macrophage phenotyping, isolation, transcriptome and proteome analyses will shed new light into the contribution of macrophages to the pathogenesis of RAS diseases.
Future directions
We have highlighted here how recent advances in understanding macrophage heterogeneity may contribute to deciphering mechanisms in RAS-related diseases. We propose a first step being to move away from histology with pan macrophage markers and instead adopt flow cytometry to characterise the identity and function of resident versus infiltrating macrophages at different times of Ang II-induced disease and in different tissues. However, a further challenge awaits in the characterisation of human myeloid cells, where in contrast to the well-characterised mouse macrophage populations, there is a profound lack of delineating surface markers for tissueresident versus infiltrating macrophages and activated macrophages subsets [20] . Ultimately, if we can elucidate precisely which macrophage subsets are functionally important in driving inflammation and fibrosis characteristics of these RASassociated diseases, we may be able to develop therapeutics to shift them toward non-disease-causing subsets.
